Loading...

CORT CORCEPT THERAPEUTICS INC Product Launches 8-K Filing

CRCP

CRT

CORCEPT THERAPEUTICS INC

(CORT)

2025 8-K

Show Summary

Show Summary

Financial Statements

FDA Application

Financial Results

Financial Results

Earnings Report

Annual Meeting Approval

Earnings Reports

Sublease Agreement

Financial Results and Corpo...

Financial Results and Stock...

Legal Dispute Outcome

Bylaw Amendment

Earnings Report

Financial Results and Corpo...

Annual Meeting Approval

Financial Results Announcement

Financial Results and Corpo...

Settlement of Securities Cl...

External Links:

On March 31, 2025, Corcept Therapeutics announced that its Phase 3 trial for relacorilant plus nab-paclitaxel in ovarian cancer met its primary goal of improved progression-free survival.

AI Assistant

CORCEPT THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.